Low nonfasting triglycerides and reduced all-cause mortality: A mendelian randomization Study

Clinical Chemistry

Volumn 60, Issue 5, 2014, Pages 737-746

  Thomsen, Mette ^a,b   Varbo, Anette ^a,b   Tybjærg Hansen, Anne ^b,c,d   Nordestgaard, Børge G ^a,c,d  

^a Mental Health Services CPH   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c FREDERIKSBERG HOSPITAL   (Denmark)

^d Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL;

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; CONCENTRATION (PARAMETERS); FOLLOW UP; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MENDELIAN RANDOMIZATION ANALYSIS; MORTALITY; TRIACYLGLYCEROL BLOOD LEVEL;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL; DATA INTERPRETATION, STATISTICAL; DENMARK; HUMANS; KAPLAN-MEIER ESTIMATE; LIPOPROTEIN LIPASE; MENDELIAN RANDOMIZATION ANALYSIS; MORTALITY; POLYMORPHISM, GENETIC; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TRIGLYCERIDES;

EID: 84899549076     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.219881     Document Type: Article

References (36)

1. Wittrup HH, Tybjaerg-Hansen A, Abildgaard S, Steffensen R, Schnohr P, Nordestgaard BG. A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. J Clin Invest 1997;99:1606-13.
2. Nordestgaard BG, Abildgaard S, Wittrup HH, Steffensen R, Jensen G, Tybjaerg-Hansen A. Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation 1997;96:1737-44.
3. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999;99:2901-7.
4. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308.
5. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309-16.
6. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S et al. Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation 2007;115:450-8.
7. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008;118:993-1001
8. Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008;322:1702-5.
9. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
10. De CR, Talmud PJ, Merlini PA, Foco L, Pastorino R, Altshuler D et al. Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction. Atherosclerosis 2011;214:397-403.
11. Varbo A, Nordestgaard BG, Tybjaerg-Hansen A, Schnohr P, Jensen GB, Benn M. Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population. Ann Neurol 2011;69:628-34.
12. Jorgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjaerg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 2013;34:1826-33.
13. Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013;61:427-36.
14. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl 2004;5:81-7.
15. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1-22.
16. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey SG. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008;27:1133-63.
17. Brunzell JD, Deeb Ss. Familial lipoprotein lipase deficiency, Apo C-II deficiency, and hepatic lipase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001;2789-816.
18. Gaudet D, Methot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr Opin Lipidol 2012;23:310-20.
19. Eriksson M, Larsson M, Caraballo R, Enquist PA, Elofsson M, Olivecrona G, Nilsson SK. Novel small molecule lipoprotein lipase activator LP071 improves plasma lipid parameters in vivo [Abstract]. Oral session presented at: 81st Congress of the European Atherosclerosis Society; 2013 Jun. 2-5; Lyon. http://www.eas-society.org/fileArchive/Press %20release-LP071- lipoprotein%20lipase%20 activator-June%203-2013.pdf (Accessed January 2014).
20. Wittrup HH, Tybjaerg-Hansen A, Steffensen R, Deeb SS, Brunzell JD, Jensen G, Nordestgaard BG. Mutations in the lipoprotein lipase gene associated with ischemic heart disease in men. The Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol 1999;19:1535-40.
21. Wittrup HH, Nordestgaard BG, Steffensen R, Jensen G, Tybjaerg-Hansen A. Effect of gender on phenotypic expression of the S447X mutation in LPL: the Copenhagen City Heart Study. Atherosclerosis 2002;165:119-26.
22. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897-908.
23. Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and all-cause mortality: the Copenhagen City Heart Study. Eur Heart J 2010;31:1624-32.
24. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999;150:341-53.
25. Palmer TM, Sterne JA, Harbord RM, Lawlor DA, Sheehan NA, Meng S et al. Instrumental variable estimation of causal risk ratios and causal odds ratios in Mendelian randomization analyses. Am J Epidemiol 2011;173:1392-403.
26. Nordestgaard BG, Stender S, Kjeldsen K. Reduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall. Arteriosclerosis 1988;8:421-8.
27. Nordestgaard BG, Zilversmit DB. Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits. J Lipid Res 1988;29:1491-500.
28. Shaikh M, Wootton R, Nordestgaard BG, Baskerville P, Lumley JS, La Ville AE et al. Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb 1991;11:569-77.
29. Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol 1995;15:534-42.
30. Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008;299:2524-32.
31. Johannsen TH, Kamstrup PR, Andersen RV, Jensen GB, Sillesen H, Tybjaerg-Hansen A, Nordestgaard BG. Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. J Clin Endocrinol Metab 2009;94:1264-73.
32. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012;380:572-80.
33. Varbo A, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, while elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 2013;128:1298-309.
34. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL et al. Triglyceriderich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:1345-61.
35. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
36. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, III, Leiter LA, Linz P et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.